HD-OPM Archive
Topics › GLP-1 drugs (semaglutide, tirzepatide)

How semaglutide appears to repair cartilage in mice and humans, independent of weight loss

Louis Nervegna · Mar 27, 2026 · ♥ 8 reactions · 2 comments · original Facebook post
GLP-1 drugs (semaglutide, tirzepatide)Weight, visceral & liver fat
AI summary & key facts

Louis shares a ScienceAlert article on the semaglutide osteoarthritis study. Semaglutide reprogrammed the metabolism of cartilage-forming cells, reduced pain and cartilage degeneration, and in mice caused fewer bone spurs; the authors describe a weight-loss-independent repair mechanism.

More information on this remarkable recent human clinical trial showing that semaglutide (ozempic) can regrow knee cartilage by 17%.

This article delves into the mechanisms by which it appears to work.

Also see this previous post on the study: ↪ Semaglutide raised knee cartilage thickness 17% in 6 months in a small pilot.

Quoted:

The drug behind Ozempic and Wegovy is best known for treating type 2 diabetes and helping people lose weight. But the new study found semaglutide appears to protect joints in mice through a mechanism that's not about easing pressure through weight loss.

Instead, the drug reprograms the metabolism of cells that synthesize and maintain healthy cartilage, allowing them to generate more energy.

"This work not only highlights the potential off-target effect of semaglutide as an effective drug to treat metabolic osteoarthritis," the team from China and the US writes in their published paper, "but also reveals a weight loss-independent repair mechanism."

Existing osteoarthritis therapies are generally palliative. So while they may alleviate the symptoms, they don't address the underlying cause.

But semaglutide appears to affect joint health at a fundamental level. In mice and humans with obesity and osteoarthritis, treatment with semaglutide reduced pain and decreased cartilage degeneration. Mice also had fewer bone spurs and less severe lesions in their joint membranes.

When the researchers compared cartilage from treated and untreated mice, they detected changes in the expression of nearly 8,300 proteins.

They included a crucial control: a "pair-feeding" group that ate the same amount as the semaglutide-treated mice. Even with comparable weight changes, the pair-feeding group did not receive the same cartilage protection, suggesting a weight-loss-independent effect on the joint itself.

Yet it seems the most important biological pathway altered by semaglutide is the "GLP-1R-AMPK-PFKFB3 axis," a cascade of compounds that affects how various cells produce energy.

By initiating this cascade of enzymes, semaglutide alters the metabolic processes used by chondrocytes (cells found in healthy cartilage), making them more efficient and allowing them to survive.

As the researchers revealed, a process called glycolysis generated most of the energy for chondrocytes in osteoarthritis-affected mice.

Glycolysis doesn't require oxygen, so it supplies energy quickly during stressful, high-intensity exercise, like the morning sprint to catch the garbage truck. Yet, due to the lack of oxygen, glycolysis produces only two net ATP (energy-providing) molecules per glucose molecule.

But after semaglutide treatments, a process called oxidative phosphorylation (OXPHOS) became the preferred metabolic pathway for chondrocytes. Unlike glycolysis, OXPHOS uses oxygen and produces much more ATP, up to 36 molecules per glucose molecule.

To see if any of this might translate to humans, the researchers recruited 20 individuals, aged 50-75, with both obesity and osteoarthritis, and randomly divided them into two groups. One group received sodium hyaluronate (HA), a joint-lubricating, especially effective form of hyaluronic acid. The other group received both HA and semaglutide.

At the end of the 24-week treatment period, the HA+semaglutide group experienced lower osteoarthritis pain scores and substantial improvements in knee function. MRI analysis also revealed thicker cartilage [17% increase] and recent cartilage growth in the inner joint areas that bear weight and absorb shock from daily movements.

ScienceAlertSemaglutide May Reverse Damage Caused by Osteoarthritis, Study SuggestsMedical researchers have discovered that semaglutide may reverse the debilitating tissue damage caused by osteoarthritis, the world's most common form of arthritis.sciencealert.com

#glp1HD #arthritisHD #cartilageHD #regenerativemedicineHD #semaglutideHD #miceHD #glp1arthritisHD

Research cited

← newer: Vitamin K2 reduced nocturnal leg cramps in a clinical study,older: Semaglutide raised knee cartilage thickness 17% in 6 months →